Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination

NCT00353366 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00353366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00353366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
November 16, 2006
Completion date
July 17, 2010
Enrollment
1,439 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus, rotavirus vaccines